enfortumab vedotin Padcev
Selected indexed studies
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. (N Engl J Med, 2024) [PMID:38446675]
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. (N Engl J Med, 2021) [PMID:33577729]
- Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. (J Clin Oncol, 2023) [PMID:36041086]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. (2024) pubmed
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. (2021) pubmed
- Enfortumab Vedotin. (2006) pubmed
- Enfortumab Vedotin. (2012) pubmed
- Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer. (2024) pubmed
- Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. (2023) pubmed
- Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. (2026) pubmed
- Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial. (2025) pubmed
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. (2016) pubmed
- Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. (2022) pubmed